HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Enzalutamide: Development from bench to bedside.

Abstract
Prostate tissue, whether benign or malignant, is heavily dependent on androgen receptor (AR) signaling for growth and proliferation. Androgen deprivation therapy has been standard of care for management of metastatic prostate cancer for the past 70 years. AR antagonists were developed to further abrogate signaling through this pathway by competitive inhibition of the receptor. First-generation compounds such as bicalutamide had modest efficacy, and in the setting of AR overexpression or specific mutations in the AR ligand-binding domain, these early compounds had partial agonist properties that could stimulate tumor growth. Enzalutamide was developed to overcome these deficiencies, and here, we present the story of its preclinical discovery, clinical development, and ultimate approval as a standard-of-care therapy for castration-resistant prostate cancer. Also discussed are ongoing efforts to elucidate mechanisms of resistance to this agent as well as studies that are investigating its role in other prostate cancer disease states and other cancer types.
AuthorsR M Bambury, H I Scher
JournalUrologic oncology (Urol Oncol) Vol. 33 Issue 6 Pg. 280-8 (Jun 2015) ISSN: 1873-2496 [Electronic] United States
PMID25797385 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2015 Elsevier Inc. All rights reserved.
Chemical References
  • Benzamides
  • Nitriles
  • Phenylthiohydantoin
  • enzalutamide
Topics
  • Benzamides
  • Cell Line, Tumor
  • Disease-Free Survival
  • Humans
  • Male
  • Nitriles
  • Phenylthiohydantoin (administration & dosage, analogs & derivatives, therapeutic use)
  • Prostatic Neoplasms, Castration-Resistant (drug therapy)
  • Signal Transduction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: